JNJ is trading near fair value. No urgent action needed.
QuantHub Research: Investment Thesis
Maturing Phase
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period, reflecting operational strength. The stock trades at a premium valuation with a P/E trailing and forward of 26.81 and a P/FCF of 28.22, placing it in a very expensive regime relative to its five-year history. However, the fair value estimate of $263.05 implies 14% upside, suggesting some mispricing given the earnings pressure and ongoing legal risks. The company’s strong balance sheet, pipeline growth in oncology and immunology, and strategic acquisitions support a moderate buy stance despite near-term challenges.
Johnson & Johnson is expensive due to a premium P/E of 26.81 compared to historical averages and peers trading around 16-18x forward earnings. Analyst consensus remains a buy but with cautious sentiment due to earnings pressure and legal overhangs. The market prices in stable but slower growth and ongoing risks, reflected in the very expensive valuation regime despite 14% upside to fair value.
12–18 Month Outlook
In 18 months, Johnson & Johnson is expected to achieve revenues near $100 billion with adjusted EPS around $11.5, reflecting moderate growth despite patent cliffs and legal challenges. The company’s valuation may remain pressured by ongoing litigation and earnings volatility, but pipeline progress and MedTech innovation could support stabilization or modest appreciation.
Bull vs Bear
Bull Case
The company’s innovative medicine segment grew to approximately $60.4 billion in trailing twelve months revenue, driven by oncology, immunology, and neuroscience products.
MedTech segment revenue increased to about $33.8 billion with operational growth supported by acquisitions such as Shockwave and Abiomed.
Johnson & Johnson maintains a AAA credit rating and a strong balance sheet, supporting continued investment in R&D and strategic M&A.
The CEO Joaquin Duato has over 36 years of tenure with the company, providing deep institutional knowledge and stable leadership.
2026 guidance projects revenues near $100.5 billion and adjusted EPS of $11.53, indicating resilience despite patent cliffs and litigation risks.
Bear Case
Earnings declined 52.4% year-over-year in the most recent quarter, signaling significant near-term profitability pressure.
Ongoing talc litigation with over 67,000 cases and multi-billion dollar verdicts poses a substantial legal and financial risk.
Patent cliffs, especially on key drugs like Stelara, and competitive biosimilar threats could erode future revenue and margins.
Integration risks from recent acquisitions such as Shockwave and delays in regulatory approval for the Ottava robotic system may hinder growth.
The stock trades at a very expensive valuation, limiting upside and increasing downside risk if growth disappoints or legal issues worsen.
Leadership & Competitive Position
Joaquin Duato
Tenure36 yrs
Beats guidance75% of qtrs
Capital allocationExcellent
Joaquin Duato has over 36 years with Johnson & Johnson, ascending through the ranks to CEO and Chairman. His tenure reflects deep institutional knowledge and a focus on aggressive M&A and R&D investments targeting sustainable growth.
Competitive Moat
stable
intangible assetsbrandcost advantage
Specific market share data is not provided, but Johnson & Johnson holds leading positions in pharmaceuticals and medical devices with a diversified portfolio and strong brand recognition.
Competitors: Pfizer (PFE), Medtronic (MDT)
Disruption: Medium due to patent cliffs and biosimilar competition in pharma and technological innovation requirements in MedTech.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
26.81x
20.99x
22.09x
3.53x
34.0x
P/S
5.77x
4.18x
4.26x
3.56x
5.77x
P/FCF
28.22x
25.71x
30.46x
16.12x
52.3x
P/S 5.77x vs 5yr range 3.56-5.77x (P25=4.1x, median=4.26x, P75=4.58x)
Approval and commercial launch of the Ottava robotic system could drive significant growth in the MedTech segment.
high
2026-Q4
Talc Litigation Resolution
A major settlement or resolution of talc litigation cases would remove a significant overhang and potentially re-rate the stock.
high
2026-Q2
Shockwave Acquisition Integration
Successful integration of Shockwave could enhance cardiovascular device revenues and operational synergies.
medium
2027-01-25
2026 Full Year Earnings Report
Earnings results and guidance updates will provide clarity on growth trajectory and margin recovery.
medium
Risks
Talc Litigation
high
Over 67,000 cases with multi-billion dollar verdicts create significant legal and financial uncertainty.
Patent Cliff Erosion
high
Loss of exclusivity on key drugs like Stelara and biosimilar competition threaten revenue and margin sustainability.
Regulatory Delays
medium
Delays in FDA approval for new products such as the Ottava robotic system could slow growth in MedTech.
Acquisition Integration
medium
Execution risks related to integrating acquisitions like Shockwave may impact operational performance.
Growth Engines
Innovative Medicinemature
The global pharmaceutical market in oncology, immunology, and neuroscience is estimated at approximately $1.5 trillion, providing a large addressable market for Johnson & Johnson's innovative medicine segment.
MedTech Devicesscaling
The medical devices market, including cardiovascular, surgery, and vision devices, is estimated around $500 billion globally, with Johnson & Johnson expanding through acquisitions and new product launches.
Johnson & Johnson Raises 2026 Revenue and EPS Guidance
The company updated its full-year outlook to revenues of $99.5-$100.5 billion and adjusted EPS of $11.43-$11.63, reflecting confidence despite patent cliffs and litigation.
2026-03-15
Anticipated Commercial Launch of Ottava Robotic System
The upcoming launch of the Ottava robotic system is a key growth driver for the MedTech segment, pending FDA approval.
2026-02-10
Integration Progress on Shockwave Acquisition
Johnson & Johnson reported ongoing integration of Shockwave, expected to boost cardiovascular device revenues.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.
Frequently Asked Questions
Is JNJ undervalued?
JNJ is currently fairly valued at $237.00 vs. our fair value estimate of $255.61 (+8% upside).
What is JNJ's fair value?
QuantHub Research estimates JNJ's fair value at $255.61 based on our proprietary valuation model incorporating historical P/S, P/E, and P/FCF multiples over a 5-year range.
What are the key risks for JNJ?
Talc Litigation: Over 67,000 cases with multi-billion dollar verdicts create significant legal and financial uncertainty. Patent Cliff Erosion: Loss of exclusivity on key drugs like Stelara and biosimilar competition threaten revenue and margin sustainability. Regulatory Delays: Delays in FDA approval for new products such as the Ottava robotic system could slow growth in MedTech.
What is the bull case for JNJ?
The company’s innovative medicine segment grew to approximately $60.4 billion in trailing twelve months revenue, driven by oncology, immunology, and neuroscience products. MedTech segment revenue increased to about $33.8 billion with operational growth supported by acquisitions such as Shockwave and Abiomed. Johnson & Johnson maintains a AAA credit rating and a strong balance sheet, supporting continued investment in R&D and strategic M&A. The CEO Joaquin Duato has over 36 years of tenure with t